MedPath

Long-term Oncologic Outcome of Breast-conserving Surgery in Breast Cancer Patients With BRCA1/2 Mutations

Completed
Conditions
BRCA1/2 Mutation
Breast-conserving Surgery
Interventions
Procedure: Breast-conserving surgery
Registration Number
NCT06429644
Lead Sponsor
Hanyang University Seoul Hospital
Brief Summary

The investigators matched BCS and mastectomy group using propensity scores and analyzed the recurrence and survival among the evenly matched patients in breast cancer patients with BRCA 1/2 mutations.

Detailed Description

The purpose of study is to assess the oncologic safety of BCS in patients carrying BRCA1/2 mutations by comparing long-term outcomes with mastectomy. The investigators matched BCS and mastectomy group using propensity scores and analyzed the recurrence and survival among the evenly matched patients. By providing insights into the feasibility of BCS for patients with BRCA1/2 mutations, the investigators aim to present evidence to aid in surgical decision-making for the care of these patients.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
4010
Inclusion Criteria
  • Primary invasive breast cancer who underwent BCS or mastectomy
  • Received a BRCA1/2 mutation test
Exclusion Criteria
  • Patients with de novo metastasis
  • Pregnancy-associated breast cancer

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Gangnam Severance HospitalBreast-conserving surgeryDepartment of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
Incheon St. Mary's HospitalBreast-conserving surgeryDepartment of Surgery, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Republic of Korea
Kyung Hee University HospitalBreast-conserving surgeryDepartment of Surgery, Kyung Hee University Hospital, Seoul, Republic of Korea
Asan Medical CenterBreast-conserving surgeryDivision of Breast Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea
Dongtan Sacred Heart HospitalBreast-conserving surgeryDepartment of Surgery, Dongtan Sacred Heart Hospital, Hallym University, Dongtan, Republic of Korea
Samsung Medical CenterBreast-conserving surgeryDivision of Breast Surgery, Department of Surgery, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Republic of Korea
Severance hospitalBreast-conserving surgeryDepartment of Surgery, Severance hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
Hanyang University Medical CenterBreast-conserving surgeryDepartment of Surgery, Hanyang University Medical Center, Hanyang University College of Medicine, Seoul, Republic of Korea
Hallym University Sacred Heart HospitalBreast-conserving surgeryDepartment of Breast \& Endocrine Surgery, Hallym University Sacred Heart Hospital, Hallym University, Anyang, Republic of Korea
Kangbuk Samsung HospitalBreast-conserving surgeryDepartment of Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
Seoul National University HospitalBreast-conserving surgeryBreast Care Center, Department of Surgery, Seoul National University Hospital, Seoul, Republic of Korea
Kyungpook National University Chilgok HospitalBreast-conserving surgeryDepartment of Surgery, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea
Keimyung University School of MedicineBreast-conserving surgeryDepartment of Surgery, Keimyung University School of Medicine, Daegu, Republic of Korea
Primary Outcome Measures
NameTimeMethod
Locoregional recurrence-free survivalDuration from diagnosis until the development of recurrence up to 10year

Recurrence in breast or chest wall and/or regional lymph nodes

Distant recurrence-free survivalDuration from diagnosis until the development of recurrence up to 10year

Recurrence in a distant organ

Recurrence-free survivalDuration from diagnosis until the development of recurrence up to 10year

Any form of disease recurrence

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Hanyang university hospital

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath